FDA Outlines Single-BLA Framework for Rare Disease Gene Editing

On October 27, 2026, the U.S. Department of Health and Human Services (HHS) announced two initiatives addressing regulatory development and treatment access for patients with rare diseases. The U.S. Food and Drug Administration (FDA) issued draft guidance on individualized genome-editing products, while the Centers for Medicare & Medicaid Services (CMS) announced plans to expand its Cell and Gene Therapy (CGT) Access Model beyond sickle cell disease.

The initiatives address two distinct barriers: how to regulate genome-editing products tailored to individual genetic variants and how to improve Medicaid access to high-cost treatments.

FDA Proposes a Single-BLA Framework for Individualized Therapies

FDA’s draft guidance, Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management, explains how sponsors may seek approval for multiple patient-specific product variants under one biologics license application (BLA) under section 351(a) of the Public Health Service Act.

Issued by the Center for Biologics Evaluation and Research (CBER), the guidance applies to genome-editing products intended for monogenic diseases caused by known pathogenic variants. These may include single-nucleotide changes, insertions or deletions. Although patients may carry different variants of the same gene, the variants covered by a single BLA must achieve the same intended editing outcome.

The central concept is the Individualized Feature Space (IFS), which defines the permitted range of variation in a product’s genome-editing components. Sponsors would establish these boundaries in the original BLA using predefined rules, specified component options or both. The proposed boundaries must be supported by appropriate clinical evidence and in vitro criteria demonstrating adequate activity and acceptable safety.

Adding Variants Without Repeating Clinical Trials

Under the proposed framework, sponsors could add a new patient-specific variant within an established IFS through a BLA supplement. FDA generally would not expect additional clinical trials when in vitro findings reliably predict clinical safety and effectiveness for the new variant.

This is not an unconditional exemption from clinical evidence. If the relationship between laboratory findings and clinical outcomes remains uncertain, additional clinical data may be needed. Expanding the IFS beyond its original boundaries would require a prior-approval supplement supported by risk-based evidence. A fundamental change in editing mechanism, such as introducing a reverse transcriptase-based editor into a product using an adenine base editor, would require a new BLA.

The distinction matters because the proposed framework could reduce the need to repeat clinical development for every qualifying variant without removing FDA’s evidence requirements.

Manufacturing, Safety and Labeling Requirements

FDA’s draft calls for manufacturing and control strategies that can accommodate all variants within the proposed IFS. These include identity, purity and potency testing, with clinically justified acceptance criteria.

Sponsors would also need predefined next-generation sequencing methods to assess off-target editing and unintended on-target changes for each relevant guide RNA and editor combination. For ex vivo products, identity controls would include confirmation of the intended edit and chain of identity.

After approval, a postapproval change management protocol could specify the in vitro evidence required to support additional variants. Labeling would identify the variants or variant classes supported by evidence and distinguish those studied clinically. Variants associated with a clinically different disease would require a new indication supported by clinical evidence.

Variants within the same individualized product would share a product name, with a targeted-gene-variant identifier used on container labels. A separate National Drug Code would not be required for each variant.

CMS Plans to Expand the CGT Access Model

CMS plans to invite manufacturers of therapies for conditions beyond sickle cell disease to participate in its voluntary CGT Access Model. The model uses outcomes-based agreements negotiated by CMS on behalf of participating state Medicaid programs.

According to HHS, the model’s first evaluation, covering sickle cell disease therapies, found that centralized negotiations reduced administrative work for states and strengthened their negotiating position by pooling beneficiaries.

CMS expects to release a Request for Applications in the coming months. The planned expansion aims to enable negotiations to begin sooner after FDA approval or licensure while allowing applications for therapies already on the market. The announcement does not establish a launch date or guarantee coverage for any particular therapy.

Regulatory Timeline and Clinical Interpretation

FDA’s draft guidance is open for public comment under docket FDA-2026-D-11783, with comments due November 27, 2026. Clinical study design and the choice between traditional and accelerated approval are outside its scope; FDA has indicated that further guidance on study design is planned.

The two initiatives address different stages of the rare-disease treatment pathway. The IFS framework could make individualized genome editing more scalable by allowing evidence from clinically studied variants to support qualifying additions using laboratory data. However, its impact will depend on how well in vitro results predict clinical outcomes, the boundaries of each approved IFS and the final guidance.

CMS’s proposed expansion addresses affordability and access rather than product development. Its practical effect will depend on implementation, participating manufacturers and state Medicaid programs, and the therapies ultimately included.

References

 FDA and CMS Announce New Steps to Advance Gene Therapies and Expand Access for Patients with Rare Diseases, US Department of Health and Human Services, 27 October 2026

Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management, US FDA, October 2026